

UnitedHealthcare Community Plan of Mississippi Medical Policy Update Bulletin: May 2024

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

Take Note

Community Plan of Mississippi to Use National Policy Versions

Effective **Jun. 1, 2024**, Community Plan of Mississippi will no longer maintain state-specific Medical Benefit Drug Policies for the following services; coverage guidelines for the state of Mississippi will now be provided in the Community Plan National policy versions listed below:

- Erythropoiesis-Stimulating Agents
- Evenity® (Romosozumab-Aqqg)
- Infliximab (Avsola[®], Inflectra[®], Remicade[®], & Renflexis[®])
- Ryplazim® (Plasminogen, Human-Tvmh)
- Saphnelo® (Anifrolumab-Fnia)
- Tezspire® (Tezepelumab-Ekko)

Medical Policy Updates

Policy Title	Status	Effective Date
Breast Reduction Surgery (for Mississippi Only)	Updated	Jul. 1, 2024
Cardiac Event Monitoring	Revised	Jul. 1, 2024
Chemotherapy Observation or Inpatient Hospitalization (for Mississippi Only)	Revised	Jul. 1, 2024
Electrical Bioimpedance for Cardiac Output Measurement	Retired	May 1, 2024
Enteral Nutrition (Oral and Tube Feeding)	Updated	May 1, 2024
Home Health, Skilled, and Custodial Care Services (for Mississippi Only)	Updated	Jun. 1, 2024
Laser Interstitial Thermal Therapy	Retired	May 1, 2024
Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions	Revised	Jul. 1, 2024
Omnibus Codes (for Mississippi Only)	Revised	Jul. 1, 2024
Orthognathic (Jaw) Surgery	Revised	Jul. 1, 2024
Patient Lifts (for Mississippi Only)	Updated	Jun. 1, 2024
Pediatric Gait Trainers and Standing Systems (for Mississippi Only)	Revised	Jun. 1, 2024
Preimplantation Genetic Testing and Related Services	Revised	Jul. 1, 2024
Prostate Surgeries and Interventions	Revised	Jul. 1, 2024
Rhinoplasty and Other Nasal Procedures	Revised	Jul. 1, 2024
Walkers (for Mississippi Only)	Revised	Jul. 1, 2024

Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
Entyvio® (Vedolizumab)	Revised	Jun. 1, 2024
Ilumya® (Tildrakizumab-Asmn)	Revised	Jun. 1, 2024
Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®)	Revised	Jun. 1, 2024
Ketalar® (Ketamine) and Spravato® (Esketamine)	Revised	Jun. 1, 2024
Maximum Dosage and Frequency	Revised	Jun. 1, 2024
Oncology Medication Clinical Coverage	Revised	Jun. 1, 2024
Oxlumo [®] (Lumasiran) and Rivfloza [™] (Nedosiran)	Revised	Jun. 1, 2024
Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®)	Revised	Jun. 1, 2024
Uplizna® (Inebilizumab-Cdon)	Revised	Jun. 1, 2024
Vyepti® (Eptinezumab-Jjmr)	Revised	Jun. 1, 2024
Xolair® (Omalizumab)	Revised	Jun. 1, 2024

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Community Plan of Mississippi Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of Medical Policies and Medical Benefit Drug Policies for UnitedHealthcare Community Plan of Mississippi is available at **UHCprovider.com/MS** > Medicaid (Community Plan) > Current Policies and Clinical Guidelines > UnitedHealthcare Community Plan of Mississippi Medical & Drug Policies.